Economic Evaluation of Heart Failure Management in Colombian Clinics

Cost effectiveness analysis of local management of patients diagnosed with heart failure disease compared with an ideal guideline-based management.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure Asthma Bronchial Diseases Cardiovascular Diseases Heart Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Asthma moderate to severe.

Treatment and study plan

Primary outcomes

To determine cost-effectiveness of Heart Failure management in 3 Heart-specialized clinics in Bogotá Colombia

Time frame: 12 months
Incremental cost-effectiveness ratio from using Symbicort as symbicort as Maintenance and Reliever Therapy (SMART) when compared with its competitive alternatives

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: EconoHeart

Important dates

Study start: 2008
Primary completion: 2008
Study completion: 2008
First posted: Mar 10, 2010
Registry last updated: Mar 10, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed